699 results found

Last week, the Federal Circuit issued its opinion in Boston University (BU) v. Everlight, in which the court found that the only asserted claim (claim 19) ...

The Patent Trial and Appeal Board recently reversed an obviousness finding of (non-signatory) Examiner Audrey Buttice, supported by Supervisory Patent Examienr (SPE) Joanne Hama...

In a precedential opinion issued on January 10, 2025, the United States Court of Appeals for the Federal Circuit reversed a district court's ruling that had invalidated claims 1-4 of U.S. Patent No. 8,101,659.

Endo Pharmaceuticals Solutions, Inc et al v. Custopharm, Inc. (Fed. Cir. July 13, 2018), is an appeal of a Delaware District Court rejecting Custopharm's validity challenge to patents...

Marijuana, for medical purposes and recreational purposes, is an area of great political, social and legal interest.

On September 15, 2021, ALJ Clark S. Cheney issued Order No. 16 granting Respondents SimpliSafe, Inc. and Vivint Smart Home, Inc.'s (collectively, "Respondents") motion for

Under 35 U.S.C. §156, a patentee can extend a patent's term to restore part of the term consumed during the Food and Drug Administration's (FDA) New Drug Application (NDA) approval process for a compound covered by the patent.

Last week, the U.S. Court of Appeals for the Federal Circuit ("CAFC") issued an opinion in Columbia Sportswear v. Seirus Innovative Accessories (No. 2018-1329, 2018-1331 and 2018-1728) (Nov. 13, 2019).

The Federal Circuit vacated a PTAB decision on patent obviousness, establishing that a provisional application must provide written description support for at least one published claim to qualify as prior art under its earlier filing date. This ruling clarifies the requirements for claiming priority from provisional applications and impacts how patent practitioners should approach provisional filing strategies.

The US Supreme Court announced its ruling May 18 in favor of Sanofi in its dispute with Amgen over the enablement requirement as it pertained to antibody claims.

In Astellas Pharma Inc. v. Sandoz Inc,, et al, following a five-day patent claims bench trial the court found asserted claims 5, 20, and 25 invalid under 35 U.S.C. § 101 even though Sandoz had not asserted 101 as defense...

In an order last month, the Delaware district court ruled that some communications involving Onyx's patent agent were not privileged and must be produced to Cipla.

On December 6, 2022, the Patent Trial and Appeal Board (PTAB) overturned a rejection of a claim to a plant extract based on patent ineligible subject matter (Appeal 2022-001062)

On July 7, 2022, Director Kathi Vidal granted Director review of the PTAB decisions in OpenSky Industries, LLC v. VLSI Technology LLC, IPR2021-01064, Paper 47 (PTAB July 7, 2022) and Patent Quality Assurance, LLC v. VLSI Technology LLC, IPR2021-01229, Paper 35 (PTAB July 7, 2022).

The Federal Circuit on February 24th affirmed the Delaware District order in Jazz Pharm., Inc. v. Avadel CNS Pharm., LLC., 2023-1186, that Jazz delist from the Orange Book its Patent 8,731,963...

In this board decision, the Patent Trial and Appeal Board (PTAB) reversed the Examiner's rejections of claims 22, 54-56, and 60-62 in US 16/765,024.

The decision in Dana-Farber Cancer Institute, Inc. v. Ono Pharmaceuticals Co., Ltd, Tasuku Honjo, E.R. Squibb & Sons, L.L.C., Bristol-Myers Squibb Company (Fed. Cir., July 14, 2020)...